CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Serological screening for IgG and IgM antibodies against COVID-19Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug1518 anti-SARS-CoV-2 convalescent plasma Wiki 0.50

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.05

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 COVID-19 Serologic Screening and a Strict Protocol in the Management of a Referral Gastrointestinal Endoscopy Unit: a Prospective Study

The novel COronaVIrus Disease 19 (COVID-19) outbreak has impacted daily activities in nearly 210 countries and territories worldwide. In Ecuador, the city of Guayaquil has nearly two-thirds of the COVID-positive patients in the country and nearly 40% of infected individuals are health-care related personnel. Nonemergent, emergent and urgent endoscopic procedures are necessary to be performed during the COVID-19 pandemic. Several experiences in the management of the endoscopic unit during the pandemic has been proposed. We aimed to prospectively evaluate a strict protocol for preventing potential nosocomial infection of COVID-19.

NCT04374123 COVID Diagnostic Test: Serological screening for IgG and IgM antibodies against COVID-19

Primary Outcomes

Description: COVID-19 infection in the staff documented via PCR

Measure: Rate of COVID-19 nosocomial infection among the endoscopy staff at the end of the 30-days study.

Time: through study completion, an average of 30 days

Description: Endoscopic records of patients treated during the COVID-19 protocol

Measure: Numbers of patients evaluated and treated during the COVID-19 outbreak in the endoscopy unit at the end of the 30-days study.

Time: through study completion, an average 30 days

Description: technical success of endoscopic procedures

Measure: Technical success rate of endoscopic procedures during the 30-days study period.

Time: through study completion, an average 30 days

Description: serum levels of IgG and IgM against COVID-19

Measure: IgG and IgM against COVID-19 in the endoscopy staff measured at the end of the study.

Time: through study completion, an average 30 days

Description: adverse events of endoscopic procedures

Measure: Adverse events rate of endoscopic procedures during the 30-days

Time: through study completion, an average 30 days

No related HPO nodes (Using clinical trials)